<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212354</url>
  </required_header>
  <id_info>
    <org_study_id>ESC-928-MOL-0000-I</org_study_id>
    <nct_id>NCT01212354</nct_id>
  </id_info>
  <brief_title>Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT</brief_title>
  <acronym>Escalox</acronym>
  <official_title>Phase III A Prospective, Randomized, Rater-blinded, Multicentre Interventional Clinical Trial. Do Selective Radiation Dose Escalation and Tumour Hypoxia Status Impact the Locoregional Tumour Control After Radiochemotherapy of Head &amp; Neck Tumours?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major clinical problem and predominant cause of death after radio-oncological treatment&#xD;
      of H+N cancers are loco-regional relapses. This randomized trial tests the hypothesis that&#xD;
      dose escalated Intensity Modulated Radiotherapy (IMRT) selectively applied to the macroscopic&#xD;
      primary tumor and involved neck nodes - which both in 80% - are hypoxic improves&#xD;
      loco-regional control by at least 15% at 2 years. IMRT is combined with concurrent Cis-Platin&#xD;
      chemotherapy. Tumor volume which correlates with number of malignant cells as well as tumor&#xD;
      hypoxia are important biological parameters which increase radio-resistance, failure of local&#xD;
      control and tumor progression. Basing on data of experimental and clinical radiation oncology&#xD;
      we consider hypoxia as a useful parameter for pre-therapeutic strati-fication in future&#xD;
      randomized radio-chemotherapy trials.&#xD;
&#xD;
      In addition, hypoxia imaging by PET can be used for testing the significance of selective&#xD;
      dose escalation on hypoxic tumor sub-volumes (&quot;Dose Painting&quot;).&#xD;
&#xD;
      As a prerequisite for such innovative studies addressing hypoxia the translational part&#xD;
      investigates the following key issues: correlation between the size of total tumor volume&#xD;
      (primary, lymph nodes) and hypoxic sub-volume, the spatial shift of the hypoxic sub-volume&#xD;
      before start of treatment and the correlation of loco-regional control and hypoxia.&#xD;
&#xD;
      Before starting the main study a pre-study to assess the occurrence of radiation induced&#xD;
      toxicities is mandatory to be performed. In a step-wise dose-escalation in a cohort-design&#xD;
      the safety of dose-escalation should be determined. Step one: 6 patients Step two: 14&#xD;
      patients. In the pre-study the 1st group (6 patients) should be treated with 2.2 Gy up to&#xD;
      77.0 Gy for DEVPT and DEVLK. After evaluation of the toxicity the next 14 patients should be&#xD;
      treated by this scheme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pre-study with sequential design is a prospective multicentre interventional pilot study&#xD;
      to assess toxicity of intensity modulated radiotherapy (IMRT) plus Cisplatin of head and neck&#xD;
      cancers&#xD;
&#xD;
      The main study is a multicenter phase III randomized trial on the effect of dose escalated&#xD;
      radiotherapy with concomitant chemotherapy to treat local advanced head and neck cancer. The&#xD;
      study compares two treatment arms:&#xD;
&#xD;
      Experimental intervention (group A): 7 weeks standard radio-chemotherapy with 20 mg/m²/d&#xD;
      Cisplatin in week 1 and 5 including simultaneous radiation dose escalation (5x2.3 Gy per week&#xD;
      up to 80.5 Gy total dose) to the primary tumour and involved neck nodes ≥ 2 cm.&#xD;
&#xD;
      The Dose Escalated tumour Volume (DEVPT) is defined by the macroscopic (Gross) primary Tumour&#xD;
      Volume (GTVPT) minus a 3 mm margin at organs at risk or at mucosal sites to reduce the risk&#xD;
      of high dose deposition at the surrounding normal tissue. All involved lymph nodes visualized&#xD;
      by CT with a minimal diameter of 2 cm are also included for dose escalation (DEVLN). The&#xD;
      DEVLN of the lymph nodes &gt; 2 cm is determined by the involved lymph node volume (GTVLN) minus&#xD;
      a margin of 3 mm at organs at risk or mucosal sites. The 3 mm margin as well as the part of&#xD;
      the target volume with suspected microscopic tumor extension receives 2 Gy per fraction.&#xD;
&#xD;
      Control intervention (group B): 7 weeks standard radio-chemotherapy with 5x2.0 Gy per week up&#xD;
      to a total dose of 70 Gy and 20 mg/m²/d Cisplatin in week 1 and 5.&#xD;
&#xD;
      In group A and B: The treatment of the elective cervical lymphatic areas is given in the same&#xD;
      session as the GTV but with a single dose of 1.6 Gy up to 56 Gy (so called simultaneous&#xD;
      integrated boost concept).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year-loco-regional control</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases (DM)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity esp. concerning salivary glands</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QoL-C30, H&amp;N 35)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects according to NCI CTC-AE (VERSION 4.0/ 10/1/2010) and LENT-SOMA</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FMISO PET/CT: Reproducibility and correlation with treatment coutcome</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free Survival (RFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Locally Advanced Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>A - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)</description>
    <arm_group_label>A - experimental</arm_group_label>
    <arm_group_label>B - control</arm_group_label>
    <other_name>IMRT-SIB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Age ≥ 18 ≤ 70 years&#xD;
&#xD;
          -  Independent of gender&#xD;
&#xD;
          -  Independent of race&#xD;
&#xD;
          -  ECOG 0 - 2&#xD;
&#xD;
          -  Tumor of oral cavity, oropharynx or hypopharynx&#xD;
&#xD;
          -  Histology: squamous cell carcinoma&#xD;
&#xD;
          -  Curative treatment intended&#xD;
&#xD;
          -  Tumor is classified as irresectable (see Appendix)&#xD;
&#xD;
          -  Woman of child-bearing age: negative pregnancy test in serum&#xD;
&#xD;
          -  Contraception in male and female patients and their partners if of childbearing&#xD;
             potential, willingness to use effective contraceptive method for the study duration&#xD;
             and 2 months post therapy&#xD;
&#xD;
          -  Sufficient bone marrow reserves during 7 days before study inclusion; (leukocytes ≥ 4&#xD;
             x 109/l, absolute no. of neutrophiles (ANC) ≥ 2 x 109/; thrombocyte count ≥ 100 x&#xD;
             109/l; Hemoglobin ≥ 10g/dl)&#xD;
&#xD;
          -  adequate liver function during 7 days before study inclusion (total bilirubine ≤ 2,5 x&#xD;
             ULN (upper limit of normal), ASAT/ ALAT ≤ 2,5 x ULN, alkaline phosphatase ≤ 2,5 x ULN&#xD;
             of the institution's normal value)&#xD;
&#xD;
          -  adequate kidney function during 7 days before study inclusion; serum creatinine ≤ 130&#xD;
             μmol/l; creatinine clearance ≥ 70 ml/min&#xD;
&#xD;
          -  all patients should have a dental examination before starting therapy and when&#xD;
             necessary be treated, adaptation of a teeth protection bar&#xD;
&#xD;
          -  a percutane feeding tube should be applied before start of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infiltration of the mandible and / or larynx&#xD;
&#xD;
          -  impaired renal and/ or liver function&#xD;
&#xD;
          -  secondary malignancy, unknown primary cancer, nasopharynx cancer or salivary gland&#xD;
             cancers&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Another cancer within 5 years of study entry&#xD;
&#xD;
          -  Serious concomitant disease or medical condition&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Women of child-bearing potential with unclear contraception (post menopausal women&#xD;
             must have been amenorrheal for at least 12 months to be considered of non-childbearing&#xD;
             potential)&#xD;
&#xD;
          -  previous treatment with chemotherapy, radiotherapy or surgery in head and neck (except&#xD;
             an excisional biopsy or biopsy for histology)&#xD;
&#xD;
          -  concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational drug within 30 days prior to study screening&#xD;
&#xD;
          -  life expectancy of &lt; 12 months&#xD;
&#xD;
          -  contraindications to receive Cisplatin&#xD;
&#xD;
          -  social situations that limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffi U. Pigorsch, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar der TU München Ismaningerstr. 22; 81675 Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Barta, Dr.</last_name>
    <phone>+49 (0)89-4140</phone>
    <phone_ext>7787</phone_ext>
    <email>sabine.barta@mri.tum.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für RadioOnkologie Strahlentherapie</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffi U. Pigorsch, Dr. med.</last_name>
      <phone>+49 (0)89-4140</phone>
      <phone_ext>-5611</phone_ext>
      <email>steffi.pigorsch@lrz.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Barta, Dr.</last_name>
      <phone>+49 (0)89-4140</phone>
      <phone_ext>7787</phone_ext>
      <email>sabine.barta@mri.tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Steffi U. Pigorsch, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Combs, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intensity modulated radiotherapy</keyword>
  <keyword>selective dose escalation</keyword>
  <keyword>hypoxia</keyword>
  <keyword>head cancer</keyword>
  <keyword>neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

